Menu
Search
|

Menu

Close
X

Marinus Pharmaceuticals Inc MRNS.OQ (NASDAQ Stock Exchange Global Market)

4.23 USD
-0.22 (-4.94%)
As of 4:00 PM EDT
Previous Close 4.45
Open 4.45
Volume 79,935
3m Avg Volume 146,011
Today’s High 4.45
Today’s Low 4.15
52 Week High 10.54
52 Week Low 2.37
Shares Outstanding (mil) 52.55
Market Capitalization (mil) 233.87
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.238
FY18
-0.897
FY17
-0.818
FY16
-1.469
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.23
Price to Sales (TTM)
vs sector
--
10.86
Price to Book (MRQ)
vs sector
4.05
4.40
Price to Cash Flow (TTM)
vs sector
--
24.08
Total Debt to Equity (MRQ)
vs sector
0.00
18.12
LT Debt to Equity (MRQ)
vs sector
0.00
12.99
Return on Investment (TTM)
vs sector
-75.69
12.65
Return on Equity (TTM)
vs sector
-77.95
17.19

EXECUTIVE LEADERSHIP

Scott Braunstein
Executive Chairman of the Board, Since 2019
Salary: --
Bonus: --
Lorianne Masuoka
Chief Medical Officer, Since 2017
Salary: $266,146.00
Bonus: $96,000.00
Enrique Carrazana
Independent Director, Since 2013
Salary: --
Bonus: --
Michael Dougherty
Independent Director, Since 2017
Salary: --
Bonus: --
Seth Fischer
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

170 N Radnor Chester Rd Ste 250
RADNOR   PA   19087-5279

Phone: +1484.8014670

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

SPONSORED STORIES